Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Infections

Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes

Bone Marrow Transplantation volume 49, pages 1205–1211 (2014)Cite this article

Subjects

Abstract

Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high post-transplantation Ab levels were independently associated with higher pre-transplantation recipient titer (mean difference 0.38 (95% confidence interval (CI), 0.26, 0.50), P<0.001). Significant associations between pre-HCT Ab titers in both patients and donors and occurrence of lower respiratory tract disease (LRD) after HCT were not observed. In conclusion, low pre-transplantation titers are associated with low Ab levels after HCT. The relationship between PIV-3 Ab levels and outcomes remain uncertain. Further study is needed to prospectively evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab to protection from infection acquisition and progression to LRD.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Nichols WG, Erdman DD, Han A, Zukerman C, Corey L, Boeckh M . Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004; 10: 58–64.

    Article  Google Scholar 

  2. Maziarz RT, Sridharan P, Slater S, Meyers G, Post M, Erdman DD et al. Control of an outbreak of human parainfluenza virus 3 in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2010; 16: 192–198.

    Article  Google Scholar 

  3. Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K . A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant 2011; 46: 1545–1550.

    Article  CAS  Google Scholar 

  4. Sydnor ER, Greer A, Budd AP, Pehar M, Munshaw S, Neofytos D et al. An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. Am J Infect Control 2012; 40: 601–605.

    Article  Google Scholar 

  5. Cortez KJ, Erdman DD, Peret TC, Gill VJ, Childs R, Barrett AJ et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001; 184: 1093–1097.

    Article  CAS  Google Scholar 

  6. Jalal H, Bibby DF, Bennett J, Sampson RE, Brink NS, MacKinnon S et al. Molecular investigations of an outbreak of parainfluenza virus type 3 and respiratory syncytial virus infections in a hematology unit. J Clin Microbiol 2007; 45: 1690–1696.

    Article  CAS  Google Scholar 

  7. Seo S, Xie H, Campbell AP, Kuypers JM, Leisenring WM, Englund JA et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplantation: viral detection in the lung predicts outcome. Clin Infect Dis 2014; 58: 1357–1368.

    Article  Google Scholar 

  8. Ustun C, Slaby J, Shanley RM, Vydra J, Smith AR, Wagner JE et al. Human parainfluenza virus infection after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Bio Blood Marrow Transplant 2012; 18: 1580–1588.

    Article  Google Scholar 

  9. Chemaly RF, Hanmod SS, Rathod DB, Ghantoji SS, Jiang Y, Doshi A et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119: 2738–2745 quiz 2969.

    Article  CAS  Google Scholar 

  10. Srinivasan A, Wang C, Yang J, Shenep JL, Leung WH, Hayden RT . Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Bio Blood Marrow Transplant 2011; 17: 1520–1527.

    Article  Google Scholar 

  11. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M . Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98: 573–578.

    Article  CAS  Google Scholar 

  12. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K . Parainfluenza virus 3 infection after stem cell transplant: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32: 413–418.

    Article  CAS  Google Scholar 

  13. Lewis VA, Champlin R, Englund J, Couch R, Goodrich JM, Rolston K et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996; 23: 1033–1037.

    Article  CAS  Google Scholar 

  14. Schiffer JT, Kirby K, Sandmaier B, Storb R, Corey L, Boeckh M . Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. Haematologica 2009; 94: 1101–1108.

    Article  Google Scholar 

  15. Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol 2002; 119: 1125–1132.

    Article  Google Scholar 

  16. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380–3389.

    Article  CAS  Google Scholar 

  17. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012; 14: 1258–1275.

    Article  CAS  Google Scholar 

  18. Falsey AR, Walsh EE . Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 1998; 177: 463–466.

    Article  CAS  Google Scholar 

  19. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C et al. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 2012; 54: 905–912.

    Article  CAS  Google Scholar 

  20. Walsh EE, Peterson DR, Falsey AR . Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 2004; 189: 233–238.

    Article  Google Scholar 

  21. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP . Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21: 3479–3482.

    Article  Google Scholar 

  22. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 531–537.

    Article  Google Scholar 

  23. Glezen WP, Frank AL, Taber LH, Kasel JA . Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984; 150: 851–857.

    Article  CAS  Google Scholar 

  24. Kasel JA, Frank AL, Keitel WA, Taber LH, Glezen WP . Acquisition of serum antibodies to specific viral glycoproteins of parainfluenza virus 3 in children. J Virol 1984; 52: 828–832.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Glezen WP, Denny FW . Parainfluenza viruses. In: AS Evans, RA Kaslow (eds). Viral Infections of Humans 1997.

  26. Henrickson KJ . Parainfluenza viruses. Clin Microbiol Rev 2003; 16: 242–264.

    Article  CAS  Google Scholar 

  27. Moscona A . Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005; 115: 1688–1698.

    Article  CAS  Google Scholar 

  28. Seo S, Campbell AP, Xie H, Chien JW, Leisenring WM, Englund JA et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19: 589–596.

    Article  CAS  Google Scholar 

  29. Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991; 29: 1175–1182.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. Vaccine 2012; 30: 3975–3981.

    Article  Google Scholar 

  31. Bosch M, Khan FM, Storek J . Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012; 19: 324–335.

    Article  Google Scholar 

  32. Kim YJ, Guthrie KA, Waghmare A, Walsh EE, Falsey AR, Kuypers J et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis 2014; 209: 1195–1204.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Chris Davis, George Counts and Zachary Stednick for data management, Tera Matson, Elsa Garnace and Jessica Yi for laboratory assistance, and Ikuyo Imayama for statistical advice. This work was partially supported by NIH grants CA18029, CA15704, HL081595, HL93294, K23HL091059 and L40AI071572. SS is a recipient of a fellowship from the Joel Meyers Memorial Fund. APC also received support from the Seattle Children’s Center for Clinical and Translational Research and CTSA grant ULI RR025014.

Author information

Author notes

  1. A P Campbell

    Present address: 7Current address: Centers for Disease Control and Prevention, Atlanta, GA, USA.,

Authors and Affiliations

  1. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    S Seo, J A Englund, T Stevens-Ayers, M Boeckh & A P Campbell

  2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    H Xie, W M Leisenring, M Boeckh & A P Campbell

  3. Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

    R A Karron & B Thumar

  4. Pediatric Infectious Diseases, Seattle Children’s Hospital, Seattle, WA, USA

    J A Englund & A P Campbell

  5. Department of Pediatrics, University of Washington, Seattle, WA, USA

    J A Englund & A P Campbell

  6. Department of Medicine, University of Washington, Seattle, WA, USA

    M Boeckh

Authors
  1. S Seo
    View author publications

    Search author on:PubMed Google Scholar

  2. H Xie
    View author publications

    Search author on:PubMed Google Scholar

  3. R A Karron
    View author publications

    Search author on:PubMed Google Scholar

  4. B Thumar
    View author publications

    Search author on:PubMed Google Scholar

  5. J A Englund
    View author publications

    Search author on:PubMed Google Scholar

  6. W M Leisenring
    View author publications

    Search author on:PubMed Google Scholar

  7. T Stevens-Ayers
    View author publications

    Search author on:PubMed Google Scholar

  8. M Boeckh
    View author publications

    Search author on:PubMed Google Scholar

  9. A P Campbell
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to A P Campbell.

Ethics declarations

Competing interests

MB and SS received research support from Ansun Biopharma. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seo, S., Xie, H., Karron, R. et al. Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. Bone Marrow Transplant 49, 1205–1211 (2014). https://doi.org/10.1038/bmt.2014.124

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/bmt.2014.124

This article is cited by

Search

Advanced search

Quick links